A blood test designed to find cancer early did not work as hoped in a major new study, according to the company that makes it. The test, called Galleri, failed to lower the number of people diagnosed ...
A closely watched clinical trial in Britain that screened blood for early detection of cancer did not show a reduction in ...
Shares in the company lost about half their value in Friday trading after the clinical trial failed to demonstrate a statistically significant reduction in stage III and IV cancers.
GRAIL (GRAL) stock plunges after NHS-Galleri trial miss for Galleri cancer test, which was added to the Hims & Hers (HIMS) platform earlier this month. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results